Recall Alert
| Drug products declared Substandard by Drug Testing laboratories Punjab |
| DRAP Alert No | No II/S/11-26-54 |
| Action Date | 16th November, 2026 |
| Target Audience | – National Regulatory Field Force – Healthcare Professional – Physician, Pharmacist, and Nurses at hospitals – General Public |
| Problem / Issue | Drug Testing Laboratories (DTL) of Punjab Province informed that the samples of below mentioned drug products have been declared as ‘Substandard’. Following are the details: |
| Sr. No. | Product Name | Name of Manufacturer/Importer | Batch Number | Remarks |
| 1 | Telosin Capsule SR 0.4mg (Tamsulosin Hydrochloride sustained release pellets eq. to Tamsulosin 0.4mg) | Briell Pharmaceuticals (Pvt.) Ltd., 538-C Sunder Industrial Estate Lahore | 57026 | Drug testing Laboratory (DTL) Punjab, Multan has declared the samples of Telosin Capsule SR 0.4mg as “Substandard” on the basis of impurity testing. |
| 2 | Bisgit 5mg tablet (Each film coated tablet contains: Bisoprolol Fumarate) | T12426 | Glitz Pharma, plot No. 265, Industrial triangle Kahuta road, Islamabad | Drug Testing Laboratory (DTL) Punjab, Rawalpindi has declared the samples of Bisgit Tablet 5mg as “Substandard” on the basis of detection of some additional peaks in assay testing. |
Therapeutic Goods (s) Affected: –
| Risk Statement: | The use of the above-mentioned “Substandard” drug product may cause serious health consequences to patients since the effect of impurities and other substances present in the products, is unknown. |
| Action Initiated | The field force of DRAP and Provincial Drug Control Departments have been asked to immediately conduct market surveys for detection of presence and removal of the affected batches from the market. Manufacturers, importers and distributors have been directed to initiate recall of the affected batches in accordance with applicable regulatory requirements. |
| Advice for Healthcare Professionals | DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned batches of the drug product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link. |
| Advice for Pharmacies/Medical stores: – | All pharmacists and chemists working at distributions and pharmacies should immediately check their stocks and stop supplying the above-mentioned batches. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units should also increase surveillance in the market to ensure effective recall of the affected products. |
| Advice for Consumers | Consumers and healthcare facilities in possession of the affected batches should immediately stop using the above-mentioned products and contact the supplier, distributor or manufacturer for return or replacement. Any adverse event or quality issue associated with the use of these products should be reported to DRAP/National Pharmacovigilance Centre. |
